

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10QSB

NANOPIERCE TECHNOLOGIES INC  
Form 10QSB  
November 15, 2004

FORM 10-QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2004

OR

[ ] TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Commission file number 33-19598-D

NANOPIERCE TECHNOLOGIES, INC.

-----  
(Exact name of small business issuer as specified in its charter)

Nevada

84-0992908

-----  
(State or other jurisdiction of  
incorporation or organization)

-----  
(I.R.S. employer  
identification number)

370 17th Street, Suite 3640  
Denver, Colorado 80202

(Address of principal executive offices)

Issuer's telephone number, including area code: (303) 592-1010

Not applicable

(Former name, former address or former fiscal year, if changed since last  
report)

Check whether the issuer (1) has filed all reports required to be filed by  
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12  
months (or for such shorter period that the registrant was required to file such  
reports), and (2) has been subject to such filing requirements for the past 90  
days. Yes X No  
---

As of November 11, 2004 there were 91,259,033 shares of the registrant's sole  
class of common shares outstanding.

Transitional Small Business Disclosure Format Yes No X  
-----

PART I - FINANCIAL INFORMATION

# Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10QSB

Item 1. Financial Statements	Page
	----
Report of Independent Registered Public Accounting Firm	F-1
Condensed Consolidated Balance Sheet - September 30, 2004	F-2
Condensed Consolidated Statements of Operations - Three months ended September 30, 2004 and 2003	F-3
Condensed Consolidated Statements of Comprehensive Loss -Three months ended September 30, 2004 and 2003	F-4
Condensed Consolidated Statement of Changes in Shareholders' Equity -Three months ended September 30, 2004	F-5
Condensed Consolidated Statements of Cash Flows - Three months ended September 30, 2004 and 2003	F-6
Notes to Condensed Consolidated Financial Statements	F-7
Item 2. Management's Discussion and Analysis	1
Item 3. Controls and Procedures	3
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings - Not Applicable	
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds - Not Applicable	
Item 3. Defaults Upon Senior Securities - Not Applicable	
Item 4. Submission of Matters to a Vote of Security Holders - Not Applicable	
Item 5. Other Information - Not Applicable	
Item 6. Exhibits and Reports on Form 8-K	4
SIGNATURES	5

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

-----

Board of Directors  
Nanopierce Technologies, Inc.

We have reviewed the accompanying condensed consolidated balance sheet of Nanopierce Technologies, Inc. and subsidiaries as of September 30, 2004, the related condensed consolidated statements of operations, comprehensive loss, and cash flows for the three-month periods ended September 30, 2004 and 2003, and the condensed consolidated statement of changes in shareholders' equity for the three-month period ended September 30, 2004. These interim condensed consolidated financial statements are the responsibility of the Company's

## Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10QSB

management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with standards of the Public Company Accounting Oversight Board (United States), the objective of which is the express of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying interim condensed consolidated financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

/s/ GELFOND HOCHSTADT PANGBURN, P.C.

Denver, Colorado  
November 8, 2004

F-1

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES  
Condensed Consolidated Balance Sheet  
September 30, 2004  
(Unaudited)

Assets  
-----

Current assets:		
Cash and cash equivalents	\$	847,718
Accounts receivable, net		10,426
Prepaid expenses		2,948
		-----
Total current assets		861,092
		-----
Property and equipment:		
Office equipment and furniture		66,356
Less accumulated depreciation		45,071
		-----
		21,285
		-----
Other assets:		
Deposits and other		19,415
Investments in affiliates (Note 3)		299,061
		-----
		318,476
		-----
Total assets	\$	1,200,853
		=====

# Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10QSB

## Liabilities and Shareholders' Equity

Current liabilities:	
Accounts payable	\$ 124,191
Note payable (Note 4)	38,118
	-----
Total liabilities (all current)	162,309
	-----
Commitments and contingencies (Notes 6 and 8)	
Shareholders' equity (Notes 5 and 6):	
Preferred stock; \$0.0001 par value; none issued and outstanding; 5,000,000 shares authorized	
Common stock; \$0.0001 par value; 200,000,000 shares authorized 90,059,033 shares issued and outstanding	9,006
Additional paid-in capital	23,744,891
Accumulated other comprehensive income	122,976
Accumulated deficit	(22,838,329)
	-----
Total shareholders' equity	1,038,544
	-----
Total liabilities and shareholders' equity	\$ 1,200,853
	=====